Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone in Advanced Soft Tissue Sarcomas
NCT00022542Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2001
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixabepilone in soft tissue sarcoma (STS), sponsored by National Cancer Institute. Primary endpoint: Confirmed Response Rate up to 5 years. Started Jun 2001; status: terminated.
02
Drugs
ixabepilone
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00022542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022542.